PhaseRx Announces Targeted mRNA Data Presentations at the Controlled Release Society Annual Meeting and Exposition
SEATTLE, July 11, 2016 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing treatments for life-threatening inherited liver diseases in children, today announced that the company will present data evaluating its mRNA Hybrid Technology platform at the 43rd Annual Meeting & Exposition of the Controlled Release Society (CRS) taking place July 17-20, 2016 in Seattle.
Presentation details are as follows:
Title: "Targeted mRNA Delivery to the Liver for Intracellular Enzyme Replacement Therapy (i-ERT)"
Presenter: Pierrot Harvie, Ph.D., associate director of Formulations at PhaseRx Session: Pre-conference Nanomedicines Symposium, 11:10 a.m. PDT on Saturday, July 16, 2016
Location: Washington Athletic Club, Crystal Ballroom, 3rd Floor
This presentation will be live streamed at https://www.youtube.com/watch?v=NAsmSxpMy2E.
Title: "Targeted Di-Block Polymers Deliver mRNA to the Liver for the Treatment of Urea Cycle Disorder"
Presenter: Debashish Roy, Ph.D., scientist II of Chemistry at PhaseRx
Poster on display: July 17-19, 2016
Location: Exhibit Hall, Washington State Convention Center Exhibit Hall, Room 4AB on level 4
About PhaseRx
PhaseRx is a leading biopharmaceutical company dedicated to developing products for the treatment of children with inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy (i-ERT). PhaseRx's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of twelve and are characterized by the body's inability to remove ammonia from the blood. The company's i-ERT approach is enabled by its proprietary Hybrid mRNA TechnologyTM platform. PhaseRx is headquartered in Seattle. For more information, please visit www.phaserx.com.
SOURCE PhaseRx, Inc.
Share this article